Mario Framil – InmunoES

Avidity of autoantibodies against type I interferons as a factor associated with neurological complications in severe COVID-19

22 de July de 2026 by Mario Framil

BackgroundAutoantibodies against type I interferons (IFNs), particularly IFN-α2 and IFN-ω, are a recognized risk factor for severe COVID-19. Their functional characterization has largely focused on their neutralizing capacity. However, antibody binding…

Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients

17 de March de 2025 by Mario Framil

During the COVID-19 pandemic, approximately 15% of patients with severe COVID-19 pneumonia were reported to have neutralizing anti-type I interferon (IFN) autoantibodies, which impaired the antiviral response and led to a poorer prognosis. However, the…